Efexor XL licence extended

Efexor XL (venlafaxine) is now indicated in moderate to severe generalised social anxiety disorder/social phobia in adults.

Efexor is also indicated in major depressive disorder and in moderate to severe generalised anxiety disorder. The recommended dose in social anxiety disorder is 75mg once daily.

If the patient has failed to respond after 12 weeks, alternative therapy should be considered. Continuation of treatment in a responding patient can be considered on an individual basis, but there is no evidence of efficacy beyond six months.

 

Further information: Wyeth 0845 3670098

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New rapidly acting insulin launched

New rapidly acting insulin launched

Lyumjev is a new 'ultra rapidly acting' formulation...